<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Cidofovir</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00369</strong>&#160; (APRD00148)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (<span class="caps">CMV</span>) retinitis in patients with <span class="caps">AIDS</span>. It suppresses <span class="caps">CMV</span> replication by selective inhibition of viral <span class="caps">DNA</span> synthesis. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00369/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00369/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00369.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00369.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00369.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00369.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00369.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00369">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IUPAC</td></tr><tr><td>[[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid </td><td><span class="wishart wishart-not-available">Not Available</span></td><td>WHO</td></tr><tr><td>Cidofovir</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>DCF, USAN, BAN</td></tr><tr><td>Cidofovirum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Vistide</td><td>Gilead</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antineoplastic-agents">Antineoplastic Agents</a></li>
<li><a href="/mesh/antiviral-agents">Antiviral Agents</a></li>
<li><a href="/mesh/anti-hiv-agents">Anti-HIV Agents</a></li>
<li><a href="/mesh/radiation-sensitizing-agents">Radiation-Sensitizing Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>113852-37-2</td></tr><tr><th>Weight</th><td>Average: 279.187<br>Monoisotopic: 279.062021707</td></tr><tr><th>Chemical Formula</th><td>C<sub>8</sub>H<sub>14</sub>N<sub>3</sub>O<sub>6</sub>P</td></tr><tr><th>InChI Key</th><td>VWFCHDSQECPREK-LURJTMIESA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">({[(2S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Diazines</td></tr><tr><th>Subclass</th><td>Pyrimidines and Pyrimidine Derivatives</td></tr><tr><th>Direct parent</th><td>Pyrimidones</td></tr><tr><th>Alternative parents</th><td>Aminopyrimidines and Derivatives; Primary Aromatic Amines; Hydropyrimidines; Organic Phosphonic Acids; Primary Alcohols; Ethers; Polyamines</td></tr><tr><th>Substituents</th><td>hydropyrimidine; primary aromatic amine; phosphonic acid; phosphonic acid derivative; ether; polyamine; primary alcohol; amine; primary amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the pyrimidones. These are compounds whose pyrimidine ring bears a ketone.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS)</td></tr><tr><th>Pharmacodynamics</th><td>Cidofovir is a new anti-viral drug. It is classified as a nucleotide analogue and is active against herpes cytomegalovirus (CMV) retinitis infection. Most adults are infected with CMV. Cidofovir suppresses cytomegalovirus (CMV) replication by selective inhibition of viral DNA synthesis. </td></tr><tr><th>Mechanism of action</th><td>Cidofovir acts through the selective inhibition of viral DNA polymerase.Biochemical data support selective inhibition of CMV DNA polymerase by cidofovir diphosphate, the active intracellular metabolite of cidofovir. Cidofovir diphosphate inhibits herpesvirus polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerase alpha, beta, and gamma(1,2,3). Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis.</td></tr><tr><th>Absorption</th><td>100%</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>537 &#177; 126 mL/kg [<span class="caps">VISTIDE</span> <span class="caps">ADMINISTERED</span> <span class="caps">WITHOUT</span> <span class="caps">PROBENECID</span>]</li>
	<li>410 &#177; 102 mL/kg [<span class="caps">VISTIDE</span> <span class="caps">ADMINISTERED</span> <span class="caps">WITH</span> <span class="caps">PROBENECID</span>]</li>
</ul></td></tr><tr><th>Protein binding</th><td>6%</td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>2.4 to 3.2 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>179 +/- 23.1 mL/min/1.73 m2 [<span class="caps">WITHOUT</span> <span class="caps">PROBENECID</span>]</li>
	<li>148 +/- 38.8 mL/min/1.73 m2 [<span class="caps">WITH</span> <span class="caps">PROBENECID</span>]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Kidney damage, fall in the number of white blood cells, decreased platelets</td></tr><tr><th>Affected organisms</th><td><ul><li>Human Immunodeficiency Virus</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.9299</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9061</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6933</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5589</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8796</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9247</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9415</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.791</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.839</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6246</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8679</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8338</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8796</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8039</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.941</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9492</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5853
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8317
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9148
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.3450 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9371
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6893
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Gilead sciences inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.gilead.com">Gilead Sciences Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td>Searched, but no interactions found.</td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>